Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page
- CheckyesterdayChange DetectedGlossary visibility controls were added (Show glossary, Hide glossary) and footer metadata was updated to Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check8 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 in the page footer.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedFooter now displays Revision: v3.3.3; the HHS Vulnerability Disclosure link and the previous Revision: v3.3.2 reference were removed.SummaryDifference0.1%

- Check58 days agoChange DetectedPublications section text was updated to clarify auto-fill from PubMed, and the revision/version numbers were updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check65 days agoChange DetectedRemoved the government funding lapse notice from the study page, which previously directed users to official status pages for operating updates.SummaryDifference0.4%

- Check87 days agoChange DetectedNew entries appear in the Study Record Dates showing Results First Submitted (2024-05-13), Results First Submitted that Met QC Criteria (2025-01-07), and Results First Posted (2025-02-03).SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.